Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases

Fineline Cube Jul 6, 2026
Company Deals

iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations

Fineline Cube Jul 6, 2026
Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Deals

WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs

Fineline Cube Jan 24, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Visirna Therapeutics Completes Enrollment in Phase III Study for FCS Drug VSA001

Fineline Cube Jan 24, 2024

Visirna Therapeutics, a Shanghai-based biopharmaceutical company, has announced the completion of patient enrollment in a...

Company Deals

Shanghai Pharmaceutical and Sino Biopharmaceutical Form Strategic Partnership for Pharmaceutical Services

Fineline Cube Jan 24, 2024

Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607), a leading pharmaceutical company based in...

Company

J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth

Fineline Cube Jan 24, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for...

Company Medical Device

Establishment Labs Launches Motiva Breast Implants in China

Fineline Cube Jan 23, 2024

Establishment Labs Holdings Inc., (NASDAQ: ESTA), a US-based medical technology company specializing in women’s health,...

Company

Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services

Fineline Cube Jan 23, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to...

Company Medical Device

Zylox-Tonbridge Medical Technology Secures NMPA Nod for Innovative Iliac Vein Stent System

Fineline Cube Jan 23, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...

Company Drug

Eisai’s Uric Acid Excretion Drug Urece Accepted for Review in China

Fineline Cube Jan 23, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that it...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for Type 2 Diabetes and Obesity Drug Trial

Fineline Cube Jan 23, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that...

Company Medical Device

Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China

Fineline Cube Jan 23, 2024

Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry,...

Company Medical Device

Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device

Fineline Cube Jan 23, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease...

Company

LifeShield Medical Launches China HQ and Advanced Heart System Factory in Suzhou

Fineline Cube Jan 23, 2024

LifeShield Medical, a leading Sino-German multinational medical device company, has announced the official operation of...

Company Deals Digital Policy / Regulatory

Tencent’s WeDoctor Teams Up with Guiyang for Digital Health Community Initiative

Fineline Cube Jan 23, 2024

The municipal government of Guiyang has entered into a strategic partnership with WeDoctor Holdings Ltd,...

Company Deals

Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment

Fineline Cube Jan 23, 2024

Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab),...

Company Drug

HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy

Fineline Cube Jan 23, 2024

China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD)...

Policy / Regulatory

Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan

Fineline Cube Jan 23, 2024

The General Office of the CPC Central Committee and State Council has released the “Implementation...

Company Drug

AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment

Fineline Cube Jan 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...

Company Drug

Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Jan 23, 2024

Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...

Policy / Regulatory

NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions

Fineline Cube Jan 23, 2024

The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...

Company Deals

Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine

Fineline Cube Jan 23, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a...

Posts pagination

1 … 435 436 437 … 690

Recent updates

  • Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology
  • Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases
  • iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations
  • Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
  • Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology

Company Deals

Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases

Company Deals

iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.